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Abstract
Significance: It is generally accepted that reactive oxygen species (ROS) scavenging molecules or antioxidants exert
health-promoting effects and thus their consumption as food additives and nutraceuticals has been greatly encouraged.
Antioxidantsmay be beneficial in situations of subclinical deficiency and increased demand or acutely upon high-dose
infusion. However, to date, there is little clinical evidence for the long-term benefit of most antioxidants. Alarmingly,
recent evidence points even to health risks, in particular for supplements of lipophilic antioxidants.Recent Advances:
The biological impact of ROS depends not only on their quantities but also on their chemical nature, (sub)cellular and
tissue location, and the rates of their formation and degradation. Moreover, ROS serve important physiological
functions; thus, inappropriate removal of ROSmay cause paradoxical reductive stress and thereby induce or promote
disease. Critical Issues: Any recommendation on antioxidants must be based on solid clinical evidence and patient-
relevant outcomes rather than surrogate parameters. Future Directions: Such evidence-based use may include site-
directed application, time-limited high dosing, (functional) pharmacological repair of oxidized biomolecules, and
triggers of endogenous antioxidant response systems. Ideally, these approaches need guidance by patient stratification
through predictive biomarkers and possibly imaging modalities. Antioxid. Redox Signal. 23, 1130–1143.
Introduction
S ince the 1970s, oxidative stress has been evoked as acontributor to pathogenesis and thousands of studies
have reported protective or therapeutic benefits of antiox-
idants in cellular and animal models of cardiovascular
(43), neurodegenerative (62), and inflammatory diseases
(75) and cancer (110) diseases. As a result, antioxidant
supplements have been promoted as nutraceuticals and
antioxidant vitamins, often with little or no clinical control
or evidence.
Failures and risks of antioxidants
However, with the exception of a few studies (50, 53, 67),
antioxidants have almost always failed to show a significant
effect in long-term clinical trials performed according to the
criteria of evidence-based medicine (132). For example, the
spin-trapping synthetic antioxidant NXY-059, developed for
acute treatment of ischemia injury due to stroke, represents
one of the most prominent and costly failures of a synthetic
antioxidant ever clinically developed (135). Another exam-
ple is the recent failure of the 2CARE study on the use of
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coenzyme Q10 in the largest ever therapeutic trial for Hun-
tington’s disease (61b).
In some recent meta-analyses, a beneficial effect of anti-
oxidants was claimed, such as for vitamin C in breast cancer
(47), atrial fibrillation (2), stroke (25), or endothelial function
(5). However, a more definitive proof of antioxidant benefit
would have been required to measure plasma levels of the
administered compounds. The latter was also a major limi-
tation in several large clinical trials, for example, the Heart
Outcomes Prevention Evaluation (HOPE) (137, 158) and the
HOPE-The Ongoing Outcomes (17). Even worse than no
effect, chronic use of multivitamins without clinical control,
especially lipid-soluble antioxidants at dosages above the
upper safety limit, may be associated with increased health
risks (Table 1) (13).
In sedentary rats, vitamin E administration reduced liver
oxidative damage, while in rats submitted to chronic exercise,
vitamin E decreased antioxidant levels (148). It remains con-
troversial whether chronic intake of high concentrations of
certain antioxidants has a harmful effect on performance and
whether this might be due to redox cycling reactions that could
even convert an antioxidant into a pro-oxidant (18, 116, 125).
Taken together, these observations indicate that to identify
efficient redox-based therapeutic strategies, there is first a need
to reevaluate the physiological and pathological relevance of
reactive oxygen species (ROS), and then to determine whether
an antioxidant approach is feasible and in which situations.
Another example of the failure of antioxidant therapy is
provided in pre-eclampsia. Some studies have reported a
modest increase in oxidative stress biomarker, F2-
isoprostane, at late stages of pregnancy (112) as well as low
levels of gamma-tocopherol may be considered as a
risk factor for pre-eclampsia (63). However, concomitant
supplementation with vitamin C and vitamin E did not pre-
vent pre-eclampsia in women at risk and, even worse, this
treatment increased the rate of births with low weight (121).
Absorption, distribution, metabolism, and excretion of
specific antioxidants are essential aspects of antioxidant
therapy that have not been analyzed in detail for many
compounds, especially for nutraceuticals. Yet, the pharma-
cokinetic (bioavailability and frequency of administration)
and pharmacodynamic (therapeutic index and onset of ac-
tion) properties of specific antioxidants are critical to assess
their clinical usefulness (11). This is best exemplified with
compounds that need to cross the blood–brain barrier (73).
Redefining oxidative stress
The term, ROS, groups a number of oxygen-containing
molecules with different chemical reactivity. ROS include
not only O2
-, hydroxyl radicals, alkoxyl and peroxyl radi-
cals, NO, and nitrogen dioxide radicals but also nonradical
species such as hydrogen peroxide (H2O2), hypochlorite,
peroxynitrite, singlet oxygen, lipid peroxides, and others. At
the enzymatic level, the discovery of superoxide dismutases
(SOD), catalase, peroxiredoxins, sulfiredoxins, and glutathi-
one peroxidases implied that the formation of at least some
forms of ROS, for example, O2
-, can be harmful if not
properly controlled (24, 90, 140).
At the chemical level, when talking about ROS and ROS
scavengers, it is crucial to know what kinds of molecules are
involved. For instance, in the case of ascorbate, this antiox-
idant avidly reacts with alkyl, peroxyl, and alpha-
tocopheroxyl radicals, modestly with superoxide, and poorly
with H2O2. While ascorbate also reacts very rapidly with
hydroxyl radicals, this unlikely contributes to its antioxidant
Table 1. Meta-Analyses and Reviews of Chronic Oral Vitamin and Antioxidant Substitution
Study type Antioxidants assessed Objectives and endpoint Conclusions
Meta-analysis
(150)
b-Carotene and vitamin E Effects on CVD-related and
unrelated mortality
and morbidity
b-Carotene possibly harmful;
vitamin E no effect
Meta-analysis
(14)
b-Carotene, vitamins
A, C, E, and selenium,
alone and mixed
Incidence of cancer
and dose–response
effect on mortality
High-dose vitamin E may increase
mortality; selenium may be
beneficial in the prevention of
cancer; other antioxidants no effect
Review (81) b-Carotene, vitamin E,
and antioxidant cocktail
Primary and secondary prevention
of CVD and progression
of intima-to-media thickening
Data do not justify supplementing
antioxidants beyond the current
dietary guidelines
Meta-analysis
(102)
Vitamin E alone
and in combination
Dose–response effect
on all-cause mortality rates
High-dose vitamin E may increase
all-cause mortality and should
be avoided.
Meta-analysis
(133)
Vitamin E All relevant CVD-related
endpoints and lipid levels
Vitamin E does not affect
CVD-related outcomes.
Meta-analysis
(36)
Vitamin E alone
and in combination
Odds ratio of relevant
CVD-related endpoints
Vitamin E no effect
Meta-analysis
(13)
b-Carotene, vitamins
A, C, E, and selenium,
alone and in combination
All-cause mortality with regard
to other factors such as dose
and type of supplement
b-Carotene and vitamins A and E
may increase mortality
Decision tree
and Markov
chain model
(33)
Vitamin E alone
and in combination
Event rates and quality-
adjusted life year
Nonselective application
of high-dose vitamin E
does more harm than good
CVD, cardiovascular disease.
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activity because hydroxyl radicals are so reactive that they
react with essentially all molecules at diffusion-controlled
rates so that ascorbate will always be outcompeted.
Originally, the term oxidative stress was primarily defined
by quantitative deviation from a supposedly neutral steady-
state level of ROS (136, 140). Quantitative deviation means a
state where either increased formation of ROS or diminished
cellular antioxidant defense leads to disequilibrium and a
shift in the cellular redox balance (Fig. 1). However, we now
know that for ROS, as for many other messengers, cellular
levels are less relevant compared with subcellular concen-
trations (20, 68).
Quantity, that is, deviation from an overall equilibrium, on its
own cannot explain or define oxidative stress. In fact, at least in
many experimental models, only very moderate overall in-
creases in ROS levels are observed, yet correlating with ap-
preciable dysfunction and accumulation of relevant biomarkers
(154). Therefore, in addition to quantitative accumulation of
ROS, the oxidative stress concept needs to integrate other fea-
tures of ROS such as their subcellular or tissue location, che-
mical nature (e.g., O2
-, H2O2, ONOO
-), kinetics of formation
and degradation, and time of exposure (Fig. 2) (76). Examples
include the expression of NOX1 in hypertension, causing only a
small increase in ROS (154), but via its caveolar localization, its
product O2
- interferes with NO formation and its vasodilator
function (88); conversely, H2O2 induces endothelial nitric oxide
synthase (eNOS) and is a vasodilator (34, 100).
Physiological functions of ROS
Another potential problem of antioxidants is the many
physiological functions of ROS. The discovery of NOX
isozymes, the only known enzyme family with the sole pur-
pose of producing ROS, indicated that at least certain ROS
are physiologically essential. For a long time, and still for
newcomers to the field, it was considered that the increased
formation of ROS equates to oxidative stress and represents a
biochemical accident that can be prevented by systemic an-
tioxidant treatment (mostly cell culture or animal-based
studies using high doses of the drug). This misconception is
based on the wrong assumption that ROS fulfill no physio-
logical function. The first description was the role of NOX2
(then termed gp91phox) in immunocyte oxidative burst.
Other NOX isoforms have different physiological roles in
nonphagocytic cells, for example, in hearing (111), thyroid
hormone synthesis (32) and angiogenesis, and the constric-
tion of the ductus arteriosus (72). Furthermore, ROS play
important roles in normal cellular function, including dif-
ferentiation, proliferation, aging, and repair processes (124).
Nitric oxide/nitrogen monoxide (NO) and H2O2 seem to act
primarily as messenger molecules, for example, they essen-
tially contribute to vasodilation, proliferation (103), and pro-
mote or counteract programmed and spontaneous cell death
(apoptosis and necrosis) (12, 147).
In working muscles, ROS are generated in the microcircu-
lation, sarcolemma, and mitochondria (64) as part of a ben-
eficial physiological response. Depending on mode, intensity,
and duration of the exercise, antioxidants thus affect exer-
cise capacity and adaptation processes (Fig. 3). For example,
antioxidants, such as vitamins C and E, appear to blunt exercise-
induced mitochondrial biogenesis (116); even anaerobic exer-
cise, for example, strength training, can be affected with respect
to muscle strength and hypertrophy (94, 117). Other observa-
tions indicate that vitamin C supplementation decreases oxi-
dative stress and might increase exercise performance only in
those subjects with low initial concentration of vitamin C (114).
Both the redefinition of oxidative stress (from a global
redox disequilibrium to very subtle, even subcellular chan-
ges) and the many physiological functions of the same ROS
that also cause disease may explain why systemic and
chronically applied antioxidants may not necessarily have
beneficial effects or even cause reductive stress or harm (9).
ROS
Exogenous
Antioxidants
Neutral or
beneficial
Detrimental
FIG. 1. Classical view on oxidative stress and antioxi-
dants. Initially reactive oxygen species (ROS) were seen as a
metabolic by-product that in low concentrations is neutral or
beneficial (having signaling effects), but in higher concentra-
tions can lead to a cellular, tissue, or even whole body redox
imbalance with detrimental consequences. Hence, it was seen
feasible to initiate systemic treatment with ROS scavengers as
antioxidants to reverse this imbalance by reducing ROS levels.
Such exogenous antioxidants were not expected to have any
possible side effects. To see this illustration in color, the reader
is referred to the web version of this article at www.liebertpub
.com/ars
ROS
Enzyme
Source A
Detrimental
Enzyme
Source B Inhibitor drug
Beneficial
Signalling
(endogenous)
Antioxidant
Enzymes
Functional
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Damaged
targets
Quantity
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FIG. 2. Refined scheme and major changes in our
understanding of oxidative stress and possible interven-
tions. ROS are now viewed not necessarily as disease-
triggering molecules but also as essential signaling messengers.
The distinction between beneficial and detrimental effects of
ROS cannot be defined by overall cell, tissue, or whole body
quantity of ROS formation. Instead, these differences may be
due to different sources of ROS in different cellular and sub-
cellular compartments (physiological and nonphysiological),
the type of ROS being formed (e.g., superoxide vs. hydrogen
peroxide). In light of the many negative results with broad
systemic antioxidants, new therapeutic approaches may in-
clude more targeted or specific antioxidants, limiting antioxi-
dants only to situations with acute and extremely high ROS
levels, or indirect antioxidant mechanisms by upregulating
endogenous antioxidant defense systems. To see this illustra-
tion in color, the reader is referred to the web version of this
article at www.liebertpub.com/ars
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For example, ROS formed during the oxidative burst of
phagocytic cells protect against infection and tumor cells,
which imposes the risk of any chronically applied antioxidant
(71, 118, 129). On the other hand, experimental data support
the hypothesis that vitamin C affects epigenetic reprogram-
ming toward less invasiveness of tumor cells (44, 149, 156).
Paradoxes between in vitro versus in vivo and animal
versus human studies
One potentially large problem in the field of ROS may be
the use of in vitro models to observe cytoprotective effects of
antioxidants. Standard cell culture, isolated organs, and cell-
free models represent artifact-prone conditions due to a very
high partial oxygen pressure of about 0.2mM (79). In addition,
the frequently published exposure of cells to a bolus of high
micromolar concentrations of an oxidant is nonphysiological,
even if this may be reached in some subcellular compartments
or intercellular spaces. It likely impairs cellular antioxidant
defenses in a manner that is hardly ever seen in vivo (46).
Yet, it remains puzzling why so many in vivo animal studies
that have shown beneficial effects of antioxidants were later not
translatable into the clinic because they failed to show benefit or
in some studies, HOPE (95, 157), HOPE-TOO (89), a pro-
spective study with vitamin C in postmenopausal women with
diabetesmellitus (82), and a prospective cohort study conducted
among 83,639 healthy male US physicians (107), worsened
outcome (Table 1). However, these and other studies often do
not monitor plasma concentrations of the supplemented anti-
oxidant. Measurement of drug levels in tissues where the dis-
ease process is to bemodified by the drug is not always practical
(e.g., the central nervous system, heart) and target engagement
biomarkers may be more helpful. Nevertheless, even in these
cases, plasma levels of the drug serve important purposes, such
as determination of drug safety and effective drug range.
Thus, it is possible that the lack of response had pharma-
cokinetic rather than pharmacodynamic reasons. In the Eu-
ropean Prospective Investigation into Cancer (EPIC)-Norfolk
study, vitamin C concentrations correlated with lower risk of
all-cause mortality (77) and, in a meta-analysis of prospective
studies, with a lower risk of stroke (25).
According to meta-analyses, long-term, high-dose N-
acetylcysteine (NAC) treatment may improve the clinical
complications of patients with chronic obstructive pulmonary
disease (134) and the prophylactic use of NAC could reduce
the incidence of postoperative atrial fibrillation and all-cause
mortality in adult patients undergoing cardiac surgery (87).
However, apart from a possible publication bias, such non-
interventional observational studies and correlations cannot
establish cause–effect relationships.
Other reasons for the failure of chronic oral antioxidant
therapy may include the slow reaction constants between
superoxide and vitamins C and E (3.3 · 105 and 4.9 · 103 m-
1s-1, respectively, compared with 1.9 · 1010 mol-1 s-1 for the
reaction constant between NO and superoxide) (141).
Moreover, the inclusion criteria for patients can never be as
restrictive as in preclinical studies, and in some cases, the
disease may be at different stages of progression or clinical
manifestation. In addition, as indicated before, in most cases,
chronic, oral vitamin treatment has not been monitored con-
sistently to provide plasma level concentrations or changes in
target engagement biomarkers.
The differences between preclinical stages and clinical
settings are also affected by differences in the antioxidant
drug’s mechanism of action and especially due to pharma-
cokinetic and pharmacodynamic constraints (11). This is best
exemplified with compounds that need to cross the blood–
brain barrier (73).
Finally, it is interesting to note that basic research is biased
by the lack of publications with negative results while most
outcomes of clinical trials are reported. Therefore, it is pos-
sible that this paradox is due, in part, to an under-
representation of the real outcomes in preclinical studies.
Nonredox mechanisms of antioxidants
In other cases, the action of compounds with antioxidant
activity may actually involve nonredox mechanisms, such as
intercalation of DNA and/or inhibition of topoisomerase,
DNA polymerase, and ribonucleotide reductase (40). Flavo-
noids and other phytochemicals can bind to functionally di-
verse cellular targets and this may modulate the activity of a
large number of downstream genes (4).
Ongoing Development of Direct Antioxidants
Figure 4 depicts some conceptual strategies used to block
the imbalanced production of ROS. Despite the failures
and concerns with the use of antioxidant therapy, there are
still several clinical studies and developments ongoing to
translate the direct antioxidant principle into the clinic.
Most of the antioxidant therapies so far utilized compounds
that donate either one or two electrons, which require high
Exercise Oxidative
stress
PGC1
Mitochondrial
biogenesis
Endogenous
antioxidants
and HSPs
Hypertrophy
MAPK NF B
P70S6K
Exercise-induced
bronchoconstriction
(vitamin C)?
Cold symptoms?
(vitamin C)
Fatigability?
(N-acetylcysteine)
Recovery?
(polyphenols)
Possible
beneficial effects
Possible
adverse effects
Antioxidant
supplementation
FIG. 3. Simplified scheme of antioxidant supplementa-
tion outcomes in exercising individuals. Possible adverse
effects are linked to blunted cell signaling and adaptation to
exercise by reducing oxidative stress. The adaptations will de-
pend on the exercise mode (endurance vs. strength), but
MAPKsmay be important signaling proteins (65). The possible
positive effects could not only be linked to the exercised
muscles (reduced fatigability and improved recovery) but also
the upper respiratory system by alleviating common cold
symptoms and exercise-induced bronchoconstriction (10, 51,
52, 101). HSP, heat shock proteins (e.g., HSP70); JNK, c-Jun
N-terminal kinases; MAPK, mitogen-activated protein kinases
(p38, ERK1/2 and JNK); NFjB, nuclear factor kappa B (tran-
scriptions factor); PGC1a, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha. Endogenous antioxidants
include superoxide dismutase, catalase, and glutathione per-
oxidase. To see this illustration in color, the reader is referred to
the web version of this article at www.liebertpub.com/ars
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concentrations and impose the risk of converting the anti-
oxidant into a pro-oxidant. To allow for lower doses, one
alternative approach is to use compounds that are recycled by
cellular reductases or act catalytically (90).
Recycling antioxidants
Ascorbate typically reacts with free radicals, producing an
ascorbyl radical intermediate that may be reduced back or un-
dergo further oxidation to dehydroascorbic acid, for which
specific reductases exist (86). Other recycling antioxidants in-
clude low-molecular-weight thiols (e.g., glutathione and acet-
ylcysteine), thioethers (e.g.,methionine), andmanymore. In the
case of vitamin E (a-tocopherol, in which case recycling de-
pends on nonenzymatic reactions), BO-653 was developed as a
synthetic, improved vitamin E-like molecule for the treatment
of cardiovascular disease (intimal hyperplasia), but it failed in
clinical trials (28). Other examples are the above-mentioned
synthetic antioxidant NXY-059 that failed to improve outcomes
in stroke patients (135) or coenzyme Q10, which failed to im-
prove prognosis of patients with Huntington’s disease (61b).
The glutathione peroxidase mimetic, ebselen (2-phenyl-
1,2-benzoisoselenazol-3(2H)-one), was once considered a
promising synthetic antioxidant since it reacts rapidly with
peroxides (106, 153) and peroxynitrite (98), preventing lipid
peroxidation and oxidative damage of other biomolecules.
However, ebselen failed due to severe liver toxicity and in-
hibition of thiol-dependent enzymes (29). Compounds with a
metal center such as SOD or catalase can in principle detoxify
O2
- and H2O2 in a catalytic manner.
Trace elements such as zinc and selenium may augment
antioxidant enzyme activity, but it will be difficult to ascribe
their beneficial properties to modulating oxidative stress and
not to other effects related to their function as cofactors of
nonredox proteins. Metal porphyrins (FeTMPyP, FeTMPS,
MnTBAP) were not only developed as SOD mimetics
(61, 115) but unfortunately also showed pro-oxidative ac-
tivities in biological systems and, so far, have not reached the
stage of clinical application.
A possible alternative includes mitochondria-targeted
SOD mimetics, for example, Mn(III) 5,10,15,20-tetrakis(N-
methylpyridinium-2-yl)porphyrin (MnTM-2-PyP(5+)) (7, 8),
or the so-called next-generation SODmimetics. This compound
class includes Mn-pentaazamacrocycles such as GC4403 (6,
128). This and other members of the Mn-pentaazamacrocyclic
ligand class of SOD mimetics function by a one-electron redox
cycle, with oxidation of Mn(II) being the rate-determining
step (6).
In animal models of oxidative stress caused by total body
irradiation, GC4403 increased survival, decreased intestinal
apoptosis, protected lymphoid and hematopoietic tissues
(143), and reduced the incidence and severity of radiation-
induced mucositis (108). A related compound, GC4419, is
currently in Phase IIa testing (NCT01921426) in patients
undergoing standard chemoradiation treatment of head and
neck cancer, a setting in which up to 80% of patients develop
severe oral mucositis.
Mitochondria-targeted antioxidants
The direct and specific targeting of mitochondrial ROS
formation by mitochondria-targeted antioxidants is another
strategy still pursued to date. This will decrease mitochondrial
ROS and prevent oxidative damage of important mitochon-
drial structures from ROS produced by extramitochondrial
sources (e.g., mitochondrial DNA is not well protected since
efficient DNA repair systems do not exist in the matrix).
One of the first examples for this class of compounds was
mitoquinone (1, 80), a quinone coupled to triphenylpho-
sphonium, leading to significant accumulation in mitochon-
dria. mitoTEMPO is another promising candidate for
targeting mitochondrial ROS as it prevents adverse effects of
angiotensin-II in experimental hypertension (30). A draw-
back of this strategy could be that these compounds require
viable mitochondria with a certain membrane potential for
uptake, which could limit their accumulation and accordingly
antioxidant potency, especially in dysfunctional ROS-
producing mitochondria. Several candidates of these
mitochondria-targeted antioxidants are currently in late-
phase clinical trials (109, 138).
Pharmacokinetic targeting
Another clinical approach to overcome the limitations or
lack of evidence of chronic oral antioxidant therapy is the
short-term infusion of antioxidants such as vitamin C. Positive
reports include the reduction of histamine levels in allergy
(45), enhanced hearing recovery in idiopathic sudden hearing
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FIG. 4. Conceptual approach to
the use of small molecules as direct
and indirect antioxidants. The
main sources of ROS production in-
clude NOX, mitochondria, xanthine
oxidase, and other enzymes. Direct
antioxidants (green) react with ROS
and, if properly handled, may de-
crease oxidative stress. Indirect an-
tioxidants (orange) activate cellular
antioxidant defenses, such as NRF2-
mediated gene transcription, and
provide a supplemental enzymatic
armamentarium to maintain redox
homeostasis. To see this illustration
in color, the reader is referred to the
web version of this article at www
.liebertpub.com/ars
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loss (74), anti-inflammation improved recovery and lower rate
of complication in pancreatitis (35), reduction of postzoster
neuralgia (130), and reduction of gastrointestinal symptoms,
fatigue, and pain in advanced cancer (22). The mechanistic
rational is that such acute parenteral treatment targets massive
inflammation-associated ROS generation and any side effects
due to interference with physiological functions of ROS, such
as in chronic oral therapy, are not observed.
A recent phase-I study investigating primarily safety of
high-dose vitamin C infusion reported also positive effects on
inflammation and endothelial function (39). However, en-
dothelial function is only a surrogate parameter and hard
outcome studies need to show true patient-relevant benefit.
Prospective studies investigating the intravenous application
of vitamin C in surgery and burn patients reported improved
organ protection and function (83, 119, 142). On the other
hand, preclinical studies prove that pharmacologic vitamin C
concentrations are cytotoxic for cancer cell lines through the
generation of H2O2.
There appears to be a multifactorial process where vitamin
C induces cell cycle arrest, autophagy, apoptosis, and ne-
crosis, depending on the cell genotype, the ascorbate con-
centration, and exposure time (113). The high (millimolar)
concentrations necessary for this tumor cytotoxic effect can
only be achieved intravenously because oral administration
of vitamin C does not increase plasma levels above approx.
0.22mM (84). There are currently three phase I/IIa studies
being carried out in conjunction with the National Institutes
of Health, which examine the effects of high-dosage vitamin
C infusions adjuvant to standard therapy in the case of ad-
vanced tumors (93, 104, 152).
New Indirect Antioxidant Approaches
A different concept to antioxidant therapy follows the
proposition that it is not the antioxidant molecules, but the
antioxidant enzymes that provide relevant therapeutic benefit.
Molecules that augment the physiological antioxidant response
without being antioxidants themselves are here termed indirect
antioxidants and include NRF2 agonists and resveratrol.
NRF2 activators
The transcription factor, nuclear factor (erythroid-derived 2)-
like 2 (NRF2), is a master regulator of cell homeostasis that
regulates the expression of antioxidant and cytoprotective genes
that contain a specific enhancer sequence in their regulatory
regions termed antioxidant response element (ARE). These
genes account for more than 1% of the human genome and
include antioxidant genes,HMOX1 (coding heme oxygenase-1)
and NQO1 (coding NAD(P)H quinone oxidoreductase-1), and
gene encoding enzymes involved in glutathione metabolism or
in the generation of nicotinamide adenine dinucleotide phos-
phate (NADPH), etc. (Fig. 5A). For a detailed catalog of NRF2-
regulated genes, see Hayes and Dinkova-Kostova (48).
Modulation of NRF2 activity may provide two advantages
over direct antioxidants. First, the induction of NADPH,
GSH, and thioredoxin metabolism is a natural system, re-
sulting possibly in antioxidant activity in places where nee-
ded while leaving physiological ROS signaling intact.
Second, because proteins have a longer half-life than small-
molecule activators, the effect on the antioxidant defense
may be more prolonged.
The main mechanism of regulation of NRF2 stability is its
binding to the E3 ligase adapter kelch-like ECH-associated
protein 1 (KEAP1) (Fig. 5B). This protein targets NRF2 for
Cullin3/Rbx-mediated ubiquitination and subsequent pro-
teasomal degradation. However, a drop in GSH concentration
(characteristic of oxidant attack) or the presence of electro-
philes leads to sulfhydryl bonding or adduct formation, re-
spectively. This affects several cysteine residues in KEAP1,
among which C151, C273, and C288 appear to be the most
sensitive, probably because their pKa value is lower (pKa
4–5) compared with other cysteine residues (pKa 8.5) (21,
91). Such modification of KEAP1 leads to disruption of its
interaction with NRF2, its stabilization, nuclear transloca-
tion, and activation of about 250 ARE-containing genes.
All NRF2 agonists modify the sulfhydryl group of cysteine
residues of KEAP1 by oxidation or adduct formation. These
molecules include allyl sulfides, dithiolethiones, flavonoids,
isothiocyanates, polyphenols, and terpenoids (49). However,
electrophilic compounds may also react with redox-sensitive
cysteine residues present in the catalytic center of several
phosphatases. This interaction leads to upregulation of
signaling pathways that further impinge on NRF2 activa-
tion. For instance, carnosol (96), tert-butylhydroquinone
(127), synthetic triterpenoids (2-cyano-3,12-dioxooleana-
1,9-dien-28-oic acid-imidazolide [CDDO; CDDO-Im]) (120),
or nordihydroguaiaretic acid (126) activate AKT signaling.
Several reports demonstrate that phosphatase and tensin
homolog (PTEN), which is mutated in a large number of
human tumors, is a redox-sensitive phosphatase (78). Im-
portantly, the catalytic C124 of PTEN can be modified
through adduct formation with strong electrophiles such as
CDDO-Im (120) and tert-buthylhydroquinone (127). This
modification results in loss of its lipid phosphatase activity
and yields a more sustained activation of signaling events
downstream of PI3K. These events include the activation of
NRF2 by preventing its degradation through a KEAP1-
independent mechanism that involves its phosphorylation by
glycogen synthase-3 and further ubiquitination by a b-TrCP/
Cullin1/Rbx complex (Fig. 5C) (122, 123).
In summary, when considering electrophilic targeting to
NRF2, it is important to remember that not only KEAP1 but
also other redox-sensitive enzymes may cooperate to regulate
this antioxidant pathway.
The most compelling evidence in favor of a role of NRF2 in
prevention or protection from disease has been gathered from
results obtained with NRF2 knockout mice. With increasing
age, these mice present with chronic pathologies related to
oxidant and inflammatory stress, including cognitive deficits
(66), depressive disorder (97), and increased incidence of
lupus-like autoimmune nephritis (92). In humans, many single-
nucleotide polymorphisms have been identified in the coding
and noncoding regions of the gene encoding NRF2, NFE2L2,
and epidemiological studies have revealed significant associa-
tions of NFE2L2 haplotypes with risks in pulmonary, gastro-
intestinal, autoimmune, and neurodegenerative diseases (27).
The most successful case reported so far of an indirect
antioxidant targeting NRF2 is the ester derivative of fumaric
acid, dimethyl fumarate (DMF). DMF crosses the gastroin-
testinal barrier, after which it is converted into the active
principle monomethyl fumarate (MMF), which binds
KEAP1. This binding disrupts the KEAP1/NRF2 interaction
and leads to upregulation of the transcriptional NRF2
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signature of antioxidant genes. Topical and oral administra-
tion of DMF (as a salt solution commercialized as Fuma-
derm) was indicated as early as year 1994 for the treatment of
psoriasis before psoriasis was known to be an autoimmune
disease or the molecular targets of DMF were identified (3).
The immunomodulatory effect of DMF has been exploited
more recently for other autoimmune diseases such as lupus
erythematosus (146), asthma, and arthritis (131), and a
pharmaceutical formulation of DMF, termed FP187, is under
development for use in autoimmune diseases.
DMF is being used in the treatment of relapsing–remitting
multiple sclerosis (MS) (16). MMF is more potent than DMF
in NRF2 activation, but the former is probably metabolized
more rapidly. In an attempt to allow DMF to bypass gastric
metabolism, it has been packaged in an oral delayed-release
formulation known as BG-12. Following the success with
BG-12 in two clinical trials, CONFIRM and DEFINE, this
formulation has been commercialized as Tecfidera (16). Fi-
nally, a new formulation of MMF as a prodrug is currently in
phase I trial for MS (61a).
Other lines of research have focused on targeting NRF2 in
degenerative diseases with low-grade chronic inflammation
using very potent synthetic triterpenoids that target KEAP1/
NRF2. One of these compounds, CDDO-methyl ester (also
known as bardoxolone methyl), was studied for therapy of
diabetic nephropathy (151). The initial excitement about this
compound was hampered by the observation that in the phase
III clinical trial, termed BEACON, there was a small yet
significant increase in heart failure in the treated arm com-
pared with the placebo arm. This drawback was not related to
NRF2 targeting, but rather to alteration of the endothelin
signaling, leading to reduction in urine volume and sodium
excretion in some patients with advanced chronic kidney
disease (26). As a result, bardoxolone methyl is now being
tested in pulmonary arterial hypertension (27a, 60), mela-
noma (54), and Friedreich’s ataxia (27b). Moreover, its safety
and efficacy for chronic kidney disease are being reevaluated
(81a).
A third NRF2-activating principle is the isothiocyanate
sulforaphane. Sulforaphane has been isolated from 3-day-old
broccoli sprouts and other cruciferous vegetables as a product
of the enzymatic cleavage of the glucosinolate, glucor-
aphanin, by the plant enzyme, myrosinase (37). Due to its
electrophilic structure, sulforaphane interacts with specific
FIG. 5. Scheme on the antioxidant potential of the NRF2 signaling pathway and its pharmacologic targeting. (A)
NRF2 is a basic region leucine zipper (bZip) transcription factor that makes dimers with proteins of the small MAF family.
These heterodimers recognize an antioxidant response element (ARE) in about 250 genes (48). The consensus sequence is
taken from JASPAR (99) (B) Regulation of NRF2/KEAP1 by electrophilic compounds. Under basal homeostatic conditions,
NRF2 binds a KEAP1 homodimer through two tethering sites of low affinity (DLG) and high affinity (ETGE) located at the Neh2
domain. KEAP1 is a redox-sensitive E3 ligase adapter that leads to Cul3/Rbx-mediated ubiquitination of NRF2 and subsequent
degradation by the proteasome. Adduct formation with electrophiles induces a conformational change in KEAP1 that prevents
further degradation of NRF2 (145). (C) Regulation of NRF2/PTEN by electrophilic compounds. The lipid phosphatase activity
of PTEN eliminates 3-phosphoinositides required to activate AKT, thus yielding glycogen synthase kinase-3 (GSK-3) active.
GSK-3 phosphorylates NRF2 in several residues (DSGIS) of the Neh6 domain and creates a phosphodegron that is recognized by
the E3 ligase adapter, b-TrCP. This process leads to a Cul1/Rbx-mediated ubiquitination and further proteasome degradation of
NRF2. However, some electrophiles react with the critical C124 residue of PTEN located at the catalytic center to inhibit this
enzyme. Then, 3-phosphoinositide levels remain high, leading to enhanced activation of AKT and inhibition of GSK-3. Under
these conditions, NRF2 escapes GSK-3-mediated phosphorylation and recognition by the b-TrCP/Cul1/Rbx ubiquitin ligase
(123, 127). AKT, protein kinase B; KEAP1, kelch-like ECH-associated protein 1; PTEN, phosphatase and tensin homolog. To
see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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redox-sensitive cysteine residues in KEAP1, including
Cys151. This disrupts the Keap1/NRF2 complex and leads to
the increase in NRF2 protein levels and transcriptional ac-
tivity (31). Most clinical studies performed with sulforaphane
have used a highly standardized formulation of broccoli
sprout extracts. In contrast to DMF and bardoxolone methyl,
a drawback of sulforaphane is the absence of a pure formu-
lation that could be used clinically and the lack of commer-
cial value that could attract the strong investment that
pipelines on drug development require. Nevertheless, several
attempts are being made to provide proof of concept that
NRF2 targeting with sulforaphane has a therapeutic value.
Currently, at least 32 studies assess its clinical efficacy in
chronic diseases such as cancer, asthma, autism, schizo-
phrenia, chronic kidney disease, type 2 diabetes, and cystic
fibrosis.
Resveratrol
A comprehensive overview about resveratrol, including its
targets and findings in clinical trials, is provided in a recent
review (23) and schematized in Figure 6. The antioxidant
phytochemical resveratrol was initially viewed as a direct
ROS scavenger, but recent data suggest that its beneficial
effects—if any—are rather mediated by indirect antioxidant
mechanisms (85). Resveratrol increases the expression of
antioxidant enzymes, such as SODs, catalase, glutathione
peroxidase, and others, and reduces the expression of the
ROS-forming NADPH oxidase type 4 (NOX4) (139).
In addition, resveratrol confers antioxidant activity by in-
duction of the NRF2-heme oxygenase-1 pathway (69, 70) and
it restores the activity of eNOS by increasing the synthesis of
its cofactor, tetrahydrobiopterin (BH4) (155). There is also
good evidence that resveratrol not only acts on gene ex-
pression via miRNAs as well as epigenetic modifications via
activation of the NAD+-dependent deacetylase sirtuin 1
(SIRT1) (38, 85, 105) but also on proteins of the DNA repair
machinery, thereby contributing to genome stability (41).
The most compelling clinical studies on the use of
resveratrol in antioxidant therapy have demonstrated a re-
duction in redox biomarkers together with an increase in the
NRF2 signature (42). In some cases, preliminary evidence of
a salutary effect has been reported. Thus, resveratrol im-
proves insulin sensitivity in patients with type 2 diabetes (19).
In obese humans, resveratrol supplementation induced met-
abolic changes mimicking the effects of calorie restriction
(144). Resveratrol demonstrated anti-inflammatory, antioxi-
dant, and hypotriglyceridemic effects in healthy smokers
(15). Further phase III studies will be required to determine
real efficacy of this indirect antioxidant.
Conclusions
In view of the disparate results obtained with antioxidant
compounds ranging from possibly beneficial to many futile to
some harmful effects, it is necessary to reevaluate antioxidant
therapy with a revised concept of oxidative stress that con-
siders not only over ROS imbalance in a quantitative manner
but also the molecular nature of ROS local cellular and tissue
production and the enzymatic machinery in charge of its
regulation.
While chronic, not indicated, therapy with antioxidants
(especially lipid-soluble ones) must clearly not be re-
commended, there may be potential for the use of selective
antioxidants, such as vitamin C, in situations of deficiencies
or short-term overproduction accessible to parenteral high-
dose therapy. Whether there is room for SODmimetics needs
to be shown.
More modern indirect antioxidants that target redox en-
zymes seem to be the more promising. NRF2 agonists may
have the benefit of not causing reductive stress, but instead to
upregulate endogenous antioxidant defense systems. Other
approaches such as interfering with specific ROS-producing
enzymes directly or even functionally repairing ROS-induced
damage are discussed in another review of this Forum (see
Targets review in the same Forum). Time and clinical trials
investigating patient-relevant outcomes will tell.
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Abbreviations Used
AKT¼ protein kinase B
ARE¼ antioxidant response element
BH4¼ tetrahydrobiopterin
BO-653¼ 2,3-dihydro-5-hydroxy-2,2-dipentyl-
4,6-di-tert-butylbenzofuran
CDDO; CDDO-Im¼ 2-cyano-3,12-dioxooleana-1,9-
dien-28-oic acid-imidazolide
CVD¼ cardiovascular disease
DMF¼ dimethyl fumarate
eNOS¼ endothelial nitric oxide synthase
ERK¼ extracellular signal-regulated kinases
gp91phox¼ 91kDa membranous subunit of the
phagocyte NADPH oxidase (Nox2)
GSH¼ glutathione
H2O2¼ hydrogen peroxide
JNK¼ c-Jun N-terminal kinases
KEAP1¼ kelch-like ECH-associated protein 1
MAPK¼mitogen-activated protein kinase
miRNA¼microRNA, a small noncoding RNA
molecule
mitoTEMPO¼ (2-(2,2,6,6-Tetramethylpiperidin-1-
oxyl-4-ylamino)-2-
oxoethyl)triphenylphosphonium
chloride monohydrate
MMF¼monomethyl fumarate
MS¼multiple sclerosis
NAC¼N-acetylcysteine
NADPH¼ nicotinamide adenine dinucleotide
phosphate
NO¼ nitric oxide
NOS¼ nitric oxide synthase
NOX¼ nicotinamide adenine dinucleotide
phosphate oxidases
(1, 2, 4 isoforms)
NRF2¼ nuclear factor (erythroid-derived 2)-
like 2
NXY-059¼ disufenton sodium, a synthetic
antioxidant
O2
- ¼ superoxide anion
p38¼ p38 mitogen-activated protein kinases
PGC1a¼ peroxisome proliferator-activated
receptor gamma coactivator 1a
PTEN¼ phosphatase and tensin homolog
ROS¼ reactive oxygen species
SOD¼ superoxide dismutase
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